Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
NextCure joins Merck in an ovarian target
But the former is paying a fraction of what Merck shelled out for raludotatug.
Werner not good enough for Roche
Roche dumps another partnered asset.
BioNTech turns $800m into $1.5bn-plus
Bristol buys into the frenzy, and VEGF bispecific value inflation continues.
